image credit: Adobe Stock

LogicBio’s sun and shares rise again after FDA releases clinical hold on pediatric genome editing therapy

May 9, 2022

The sun and shares are rising again at LogicBio after the FDA lifted a clinical hold on a genome editing therapy for children with a rare disorder.

Shares of the Lexington, Massachusetts-based biotech were sent skyward by 60% as the markets opened Monday morning on the news that the phase 1/2 SUNRISE trial will get underway again. Even with that rapid climb, the shares are only worth 79 cents apiece, but the rally was much needed after the hold put a cash-strapped LogicBio in a tough position.

Read More on FierceBiotech